Prevention of HIV-1 transmission through breastfeeding: Efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high cd4 cell count (IMPAACT PROMISE): A randomized, open-label, clinical trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 77, Issue 4, 2018, Pages 383-392

  Flynn, Patricia M ^a   Taha, Taha E ^b   Cababasay, Mae ^c   Fowler, Mary Glenn ^d   Mofenson, Lynne M ^e   Owor, Maxensia ^f   Fiscus, Susan ^g   Stranix Chibanda, Lynda ^h   Coutsoudis, Anna ⁱ   Gnanashanmugam, Devasena ^j   Chakhtoura, Nahida ^k   McCarthy, Katie ^l   Mukuzunga, Cornelius ^m   Makanani, Bonus ⁿ   Moodley, Dhayendre ^o   Nematadzira, Teacler ^h   Kusakara, Bangini ^h   Patil, Sandesh ^p   Vhembo, Tichaona ^h   Bobat, Raziya ^q   Mmbaga, Blandina T ^r   Masenya, Maysseb ^s   Nyati, Mandisa ^t   Theron, Gerhard ^u   Mulenga, Helen ^v   Butler, Kevin ^c   Shapiro, David E ^c   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ZIMBABWE   (Zimbabwe)

ⁱ UNIVERSITY OF KWAZULU NATAL   (South Africa)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k Eunice Kennedy Shriver National Institute of Child Health and Development   (United States)

^l FAMILY HEALTH INTERNATIONAL   (United States)

^m University of North Carolina Project   (Malawi)

ⁿ UNIVERSITY OF MALAWI   (Malawi)

^o UNIVERSITY OF KWAZULU NATAL   (South Africa)

^p Byramjee Jeejeebhoy Medical College   (India)

^q UNIVERSITY OF KWAZULU NATAL   (South Africa)

^r KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^s UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^t UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^u UNIVERSITY OF STELLENBOSCH   (South Africa)

^v CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

more..

Author keywords

Antiretroviral therapy (ART); Breastfeeding; HIV 1; Nevirapine; Prevention of perinatal HIV 1 transmission

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AFRICA; ANTIRETROVIRAL THERAPY; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INDIA; INFANT; INFECTION RISK; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAWI; MOTHER; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PRENATAL CARE; PRIORITY JOURNAL; PROBABILITY; PUERPERIUM; RANDOMIZATION; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SKIN TOXICITY; SOUTH AFRICA; TANZANIA; TREATMENT OUTCOME; UGANDA; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; ZAMBIA; ZIMBABWE; AFRICA SOUTH OF THE SAHARA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PREVENTION AND CONTROL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TRANSMISSION;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; BREAST FEEDING; CHEMOPREVENTION; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INDIA; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; POSTPARTUM PERIOD; TREATMENT OUTCOME;

EID: 85048572083     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001612     Document Type: Article

References (29)

1. Fowler MG, Qin M, Fiscus S, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375: 1726-1737.
2. Myer L, Dunning L, Lesosky M, et al. Frequency of viremic episodes in HIV-infected women initiating antiretroviral therapy during pregnancy: A cohort study. Clin Infect Dis. 2016;64:422-427.
3. Haas AD, Msukwa MT, Egger M, et al. Adherence to antiretroviral therapy during and after pregnancy: cohort study on women receiving care in Malawi's Option B+ program. Clin Infect Dis. 2016;63: 1227-1235.
4. Gill MM, Hoffman HJ, Bobrow EA, et al. Detectable viral load in late pregnancy among women in the Rwanda Option B+ PMTCT program: enrollment results from the Kabeho Study. PLoS One. 2016;11: e0168671.
5. Van de Perre P, Kankasa C, Nagot N, et al. Pre-exposure prophylaxis for infants exposed to HIV through breastfeeding. BMJ. 2017;356:j1053.
6. Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): A randomised controlled trial. Lancet Infect Dis. 2011;11:171-180.
7. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extendeddose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: An analysis of three randomised controlled trials. Lancet. 2008;372:300-312.
8. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV transmission. N Engl J Med. 2008;359:119-129.
9. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): A randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:221-228.
10. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010; 362:2271-2281.
11. Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV- 1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): A randomised controlled trial. Lancet. 2016;387: 566-573.
12. Cohan D, Natureeba P, Koss CA, et al. Efficacy and safety of lopinavirritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS. 2015;29:183-191.
13. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breastfeeding in Botswana. N Engl J Med. 2010;362: 2282-2294.
14. Taha TE, Hoover DR, Chen S, et al. Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi. Clin Infect Dis. 2011; 53:388-395.
15. Marquez C, Okiring J, Chamie G, et al. Increased morbidity in early childhood among HIV-exposed uninfected children in Uganda is associated with breastfeeding duration. J Trop Ped. 2014;60:434-441.
16. Kuhn L, Sinkala M, Semrau K, et al. Elevations in mortality associated with weaning persist into the second year of life among uninfected infants bornt to HIV-infected mothers. Clin Infect Dis. 2010;50:437-444.
17. World Health organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva, Switzerland: World Health organization; 2013. Available at: www.who.int/hiv/pub/guidelines/arv2013/en/.Accessed August 15, 2016.
18. Zelen M. The randomization and stratification of subjects to clinical trials. J Chronic Dis. 1974;27:365-375.
19. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, version 2.0. November 2014. Available at: http://rsc.tech-res.com/docs/default-source/safety/daids-ae-grading-table-v2-nov2014.pdf. Accessed October 23, 2016.
20. Kilewo C, Karlsson K, Massawe A, et al; Mitra Study Team. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr. 2008;48:315- 323.
21. Kilewo C, Karlsson K, Ngarina M, et al; Mitra Plus Study Team. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr. 2009;52:406-416.
22. The Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV in breast-fed children: An independent patient data meta-analysis. J Infect Dis. 2004;189:2154-2166.
23. Group ISS, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373: 795-807.
24. Shapiro RL, Lockman S. Mortality among HIV-exposed infants: the first and final frontier. Clin Infect Dis. 2010;50:445-447.
25. Stranix-Chibanda L, Tierney C, Marr C, et al. Impact of tenofovircontaining triple antiretroviral therapy (ART) on bone mineral density in HIV-infected breastfeeding women in sub-Saharan Africa. HIV Pediatrics Workshop 2016; July 15-16, 2016; Durban, South Africa.
26. Mofenson LM, Baggaley RC, Mameletzis J. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31:213-232.
27. Mofenson LM. Tenofovir pre-exposure prophylaxis for pregnant and breastfeeding women at risk of HIV infection: the time is now. PLoS Med 2016;13:e1002133.
28. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Appraoch 2010 Revision. Geneva, Switzerland: World Health organization; 2010. Available at: http://apps.who.int/iris/bitstream/10665/44379/1/9789241599764-eng.pdf. Accessed August 15, 2016.
29. Myer L, Phillips TK, Hsiao NY, et al. Plasma viremia in HIV-positive pregnant women entering antenatal care in South Africa. J Int AIDS Soc. 2015;18:2004.